Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872194 · ClinicalTrials.gov registry record · NA
Evaluation of the Stinging Potential of Products in Human Eyes
A NA study, sponsored by Bayer.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02872194: Completed NA study, sponsored by Bayer.
NCT02872194 is a NA study that has completed, run by Bayer. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02872194, a NA study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist. The study design was a three cell, single blind study. Subjects were given the industry standard shampoo mixture in one eye and an exploratory sunscreen in the other as according to the randomization schedule.
Interventions
- DRUG BAY987516, Y55-170
- DRUG BAY987516, X72-151
- DRUG BAY987516, Y49-034
- DRUG Standard shampoo mixture (control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-09-05 |
| Est. Completion | 2014-09-06 |
| Phase | NA |
What the finished NCT02872194 record still lists
NCT02872194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which BAY987516, Y55-170 is the first listed.
NCT02872194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02872194 about?
NCT02872194 is a clinical study titled "Evaluation of the Stinging Potential of Products in Human Eyes". The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist. The study design was a three cell, single blind study. Subjects were give...
What is the current status of trial NCT02872194?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-09-05. Estimated completion is 2014-09-06.
What interventions are being tested in trial NCT02872194?
The interventions under investigation include: BAY987516, Y55-170 (DRUG), BAY987516, X72-151 (DRUG), BAY987516, Y49-034 (DRUG), Standard shampoo mixture (control) (DRUG).
Who is sponsoring clinical trial NCT02872194?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02872194's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI